Michael Barbella, Managing Editor06.22.22
Increasing diabetes diagnoses and new product innovation is expected to drive growth in India's insulin pens market over the next three years.
The insulin pens (diabetes care devices) sector is expected to reach roughly $400 million in 2025 as the country's diabetes cases rise and companies develop new solutions, such as Roche’s ACCU-FINE pen needles for virtually painless insulin delivery, GlobalData predicts.
India has the second-largest number of adults with diabetes globally, after China. This is due to the increasing aging population, urbanization, and sedentary lifestyle leading to less physical activity, obesity, and weight gain.
GlobalData’s report, "Insulin Pens Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast, 2015-2030," reveals that Novo Nordisk, Eli Lilly, and Sanofi were the major players in India, accounting for about 80% of the market in 2021.
“Recently, Roche Diabetes Care India launched ACCU-FINE insulin pen needles that enable easier insertion and rapid insulin flow. Focus on developing such innovative products will eventually lead to timely insulin delivery, which is crucial for the successful management of diabetes,” said Shweta Yadav, a medical devices analyst at GlobalData.
In addition, to focus on new product innovations, companies such as Novo Nordisk, Sanofi, and Roche are offering support to diabetes patients through various digital diabetes care programs in India. These programs aim to provide tailored guidance on disease and lifestyle management, usage of insulin pens, while maintaining privacy, regulatory, and quality requirements.
“New product launches and technological advancements are expected to further drive the insulin pens market, making India emerge as one of the dominant markets in the Asia-Pacific region,” Yadav said.
The insulin pens (diabetes care devices) sector is expected to reach roughly $400 million in 2025 as the country's diabetes cases rise and companies develop new solutions, such as Roche’s ACCU-FINE pen needles for virtually painless insulin delivery, GlobalData predicts.
India has the second-largest number of adults with diabetes globally, after China. This is due to the increasing aging population, urbanization, and sedentary lifestyle leading to less physical activity, obesity, and weight gain.
GlobalData’s report, "Insulin Pens Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast, 2015-2030," reveals that Novo Nordisk, Eli Lilly, and Sanofi were the major players in India, accounting for about 80% of the market in 2021.
“Recently, Roche Diabetes Care India launched ACCU-FINE insulin pen needles that enable easier insertion and rapid insulin flow. Focus on developing such innovative products will eventually lead to timely insulin delivery, which is crucial for the successful management of diabetes,” said Shweta Yadav, a medical devices analyst at GlobalData.
In addition, to focus on new product innovations, companies such as Novo Nordisk, Sanofi, and Roche are offering support to diabetes patients through various digital diabetes care programs in India. These programs aim to provide tailored guidance on disease and lifestyle management, usage of insulin pens, while maintaining privacy, regulatory, and quality requirements.
“New product launches and technological advancements are expected to further drive the insulin pens market, making India emerge as one of the dominant markets in the Asia-Pacific region,” Yadav said.